Welcome to our dedicated page for Mei Pharma news (Ticker: MEIP), a resource for investors and traders seeking the latest updates and insights on Mei Pharma stock.
Lite Strategy, Inc., formerly MEI Pharma, reports developments tied to its transition from a clinical-stage pharmaceutical issuer into a public-company digital asset treasury business. News has centered on the adoption of Litecoin (LTC) as the company’s primary treasury reserve asset, the completed corporate rebrand and Nasdaq ticker change from MEIP to LITS, and capital actions used to fund the strategy.
Company updates also cover treasury-management relationships, governance changes, and historical MEI Pharma disclosures involving cash preservation, strategic alternatives, and oncology drug candidates such as voruciclib and ME-344.
MEI Pharma, a clinical-stage pharmaceutical company, reported positive results for the third quarter fiscal year 2024, highlighting promising clinical data for voruciclib and ME-344. The ongoing Phase 1 study evaluating voruciclib plus venetoclax in R/R AML patients showed anti-leukemic activity, with complete responses and significant decreases in Mcl-1 levels. MEI's Board of Directors is focused on advancing the voruciclib program, with a cash balance of $56.6 million. MEI also initiated research on a new ME-344 formulation and decided to prioritize clinical development of voruciclib. Financially, MEI had no debt, $56.6 million in cash, and believes its cash balance is sufficient for the next 12 months.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.